Skip to main content
Top
Published in: BMC Cancer 1/2009

Open Access 01-12-2009 | Research article

Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situhybridization (FISH): pathologist assessment compared to quantitative image analysis

Authors: Gulisa Turashvili, Samuel Leung, Dmitry Turbin, Kelli Montgomery, Blake Gilks, Rob West, Melinda Carrier, David Huntsman, Samuel Aparicio

Published in: BMC Cancer | Issue 1/2009

Login to get access

Abstract

Background

In breast cancer patients, HER2 overexpression is routinely assessed by immunohistochemistry (IHC) and equivocal cases are subject to fluorescent in situ hybridization (FISH). Our study compares HER2 scoring by histopathologists with automated quantitation of staining, and determines the concordance of IHC scores with FISH results.

Methods

A tissue microarray was constructed from 1,212 invasive breast carcinoma cases with linked treatment and outcome information. IHC slides were semi-quantitatively scored by two independent pathologists on a range of 0 to 3+, and also analyzed with an Ariol automated system by two operators. 616 cases were scorable by both IHC and FISH.

Results

Using data from unequivocal positive (3+) or negative (0, 1+) results, both visual and automated scores were highly consistent: there was excellent concordance between two pathologists (kappa = 1.000, 95% CI: 1-1), between two machines (kappa = 1.000, 95% CI: 1-1), and between both visual and both machine scores (kappa = 0.898, 95% CI: 0.775–0.979). Two pathologists successfully distinguished negative, positive and equivocal cases (kappa = 0.929, 95% CI: 0.909–0.946), with excellent agreement with machine 1 scores (kappa = 0.835, 95% CI: 0.806–0.862; kappa = 0.837, 95% CI: 0.81–0.862), and good agreement with machine 2 scores (kappa = 0.698, 95% CI: 0.6723–0.723; kappa = 0.709, 95% CI: 0.684–0.732), whereas the two machines showed good agreement (kappa = 0.806, 95% CI: 0.785–0.826). When comparing categorized IHC scores and FISH results, the agreement was excellent for visual 1 (kappa = 0.814, 95% CI: 0.768–0.856), good for visual 2 (kappa = 0.763, 95% CI: 0.712–0.81) and machine 1 (kappa = 0.665, 95% CI: 0.609–0.718), and moderate for machine 2 (kappa = 0.535, 95% CI: 0.485–0.584).

Conclusion

A fully automated image analysis system run by an experienced operator can provide results consistent with visual HER2 scoring. Further development of such systems will likely improve the accuracy of detection and categorization of membranous staining, making this technique suitable for use in quality assurance programs and eventually in clinical practice.
Appendix
Available only for authorised users
Literature
1.
go back to reference Olayioye MA: Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001, 3 (6): 385-389. 10.1186/bcr327.CrossRefPubMedPubMedCentral Olayioye MA: Update on HER-2 as a target for cancer therapy: intracellular signaling pathways of ErbB2/HER-2 and family members. Breast Cancer Res. 2001, 3 (6): 385-389. 10.1186/bcr327.CrossRefPubMedPubMedCentral
2.
go back to reference Laudadio J, Quigley DI, Tubbs R, Wolff DJ: HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn. 2007, 7 (1): 53-64. 10.1586/14737159.7.1.53.CrossRefPubMed Laudadio J, Quigley DI, Tubbs R, Wolff DJ: HER2 testing: a review of detection methodologies and their clinical performance. Expert Rev Mol Diagn. 2007, 7 (1): 53-64. 10.1586/14737159.7.1.53.CrossRefPubMed
3.
go back to reference Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003, 8 (4): 307-325. 10.1634/theoncologist.8-4-307.CrossRefPubMed Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, Ayers M, Symmans WF, Pusztai L, Bloom KJ: The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist. 2003, 8 (4): 307-325. 10.1634/theoncologist.8-4-307.CrossRefPubMed
4.
go back to reference Zhou BP, Hung MC: Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol. 2003, 30 (5 Suppl 16): 38-48. 10.1053/j.seminoncol.2003.08.006.CrossRefPubMed Zhou BP, Hung MC: Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol. 2003, 30 (5 Suppl 16): 38-48. 10.1053/j.seminoncol.2003.08.006.CrossRefPubMed
5.
go back to reference Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E: Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004, 61 (23): 2965-2978. 10.1007/s00018-004-4277-7.CrossRefPubMed Menard S, Casalini P, Campiglio M, Pupa SM, Tagliabue E: Role of HER2/neu in tumor progression and therapy. Cell Mol Life Sci. 2004, 61 (23): 2965-2978. 10.1007/s00018-004-4277-7.CrossRefPubMed
6.
go back to reference Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, et al: Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol. 2005, 29 (11): 1505-1511. 10.1097/01.pas.0000172294.67409.4f.CrossRefPubMed Downs-Kelly E, Pettay J, Hicks D, Skacel M, Yoder B, Rybicki L, Myles J, Sreenan J, Roche P, Powell R, et al: Analytical validation and interobserver reproducibility of EnzMet GenePro: a second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast. Am J Surg Pathol. 2005, 29 (11): 1505-1511. 10.1097/01.pas.0000172294.67409.4f.CrossRefPubMed
7.
go back to reference Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ: Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol. 2002, 118 (3): 408-417. 10.1309/97WN-W6UX-XJWT-02H2.CrossRefPubMed Rhodes A, Jasani B, Anderson E, Dodson AR, Balaton AJ: Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors: a comparative study involving results from laboratories in 21 countries. Am J Clin Pathol. 2002, 118 (3): 408-417. 10.1309/97WN-W6UX-XJWT-02H2.CrossRefPubMed
8.
go back to reference Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, et al: A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2007, 15 (1): 94-102. 10.1097/PAI.0b013e31802ced25.CrossRefPubMed Powell WC, Hicks DG, Prescott N, Tarr SM, Laniauskas S, Williams T, Short S, Pettay J, Nagle RB, Dabbs DJ, et al: A new rabbit monoclonal antibody (4B5) for the immunohistochemical (IHC) determination of the HER2 status in breast cancer: comparison with CB11, fluorescence in situ hybridization (FISH), and interlaboratory reproducibility. Appl Immunohistochem Mol Morphol. 2007, 15 (1): 94-102. 10.1097/PAI.0b013e31802ced25.CrossRefPubMed
9.
go back to reference Garcia-Caballero T, Menendez MD, Vazquez-Boquete A, Gallego R, Forteza J, Fraga M: HER-2 status determination in breast carcinomas. A practical approach. Histol Histopathol. 2006, 21 (3): 227-236.PubMed Garcia-Caballero T, Menendez MD, Vazquez-Boquete A, Gallego R, Forteza J, Fraga M: HER-2 status determination in breast carcinomas. A practical approach. Histol Histopathol. 2006, 21 (3): 227-236.PubMed
10.
go back to reference Penault-Llorca F, Balaton A, Sabourin JC, Le Doussal V: [Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines]. Ann Pathol. 2002, 22 (2): 150-157.PubMed Penault-Llorca F, Balaton A, Sabourin JC, Le Doussal V: [Immunochemistry evaluation of HER2 status in infiltration breast cancer: technical protocol and interpretation guidelines]. Ann Pathol. 2002, 22 (2): 150-157.PubMed
11.
go back to reference McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J: HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol. 2002, 117 (6): 935-943. 10.1309/3643-F955-7Q6B-EWWL.CrossRefPubMed McCormick SR, Lillemoe TJ, Beneke J, Schrauth J, Reinartz J: HER2 assessment by immunohistochemical analysis and fluorescence in situ hybridization: comparison of HercepTest and PathVysion commercial assays. Am J Clin Pathol. 2002, 117 (6): 935-943. 10.1309/3643-F955-7Q6B-EWWL.CrossRefPubMed
12.
go back to reference Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer: an update from INQAT round III. Int J Biol Markers. 2005, 20 (3): 189-194. Interobserver reproducibility of immunohistochemical HER-2/neu assessment in human breast cancer: an update from INQAT round III. Int J Biol Markers. 2005, 20 (3): 189-194.
13.
go back to reference Interobserver reproducibility of immunohistochemical HER-2/neu evaluation in human breast cancer: the real-world experience. Int J Biol Markers. 2004, 19 (2): 147-154. Interobserver reproducibility of immunohistochemical HER-2/neu evaluation in human breast cancer: the real-world experience. Int J Biol Markers. 2004, 19 (2): 147-154.
14.
go back to reference Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M: C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol. 1994, 47 (9): 816-822. 10.1136/jcp.47.9.816.CrossRefPubMedPubMedCentral Kay EW, Walsh CJ, Cassidy M, Curran B, Leader M: C-erbB-2 immunostaining: problems with interpretation. J Clin Pathol. 1994, 47 (9): 816-822. 10.1136/jcp.47.9.816.CrossRefPubMedPubMedCentral
15.
go back to reference Nichols DW, Wolff DJ, Self S, Metcalf JS, Jacobs D, Kneuper-Hall R, Cate JCt: A testing algorithm for determination of HER2 status in patients with breast cancer. Ann Clin Lab Sci. 2002, 32 (1): 3-11.PubMed Nichols DW, Wolff DJ, Self S, Metcalf JS, Jacobs D, Kneuper-Hall R, Cate JCt: A testing algorithm for determination of HER2 status in patients with breast cancer. Ann Clin Lab Sci. 2002, 32 (1): 3-11.PubMed
16.
go back to reference Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H: Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol. 2002, 118 (5): 693-698. 10.1309/6ANB-QXCF-EHKC-7UC7.CrossRefPubMed Hsu CY, Ho DM, Yang CF, Lai CR, Yu IT, Chiang H: Interobserver reproducibility of Her-2/neu protein overexpression in invasive breast carcinoma using the DAKO HercepTest. Am J Clin Pathol. 2002, 118 (5): 693-698. 10.1309/6ANB-QXCF-EHKC-7UC7.CrossRefPubMed
17.
go back to reference Lacroix-Triki M, Mathoulin-Pelissier S, Ghnassia JP, Macgrogan G, Vincent-Salomon A, Brouste V, Mathieu MC, Roger P, Bibeau F, Jacquemier J, et al: High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. Eur J Cancer. 2006, 42 (17): 2946-2953. 10.1016/j.ejca.2006.06.020.CrossRefPubMed Lacroix-Triki M, Mathoulin-Pelissier S, Ghnassia JP, Macgrogan G, Vincent-Salomon A, Brouste V, Mathieu MC, Roger P, Bibeau F, Jacquemier J, et al: High inter-observer agreement in immunohistochemical evaluation of HER-2/neu expression in breast cancer: a multicentre GEFPICS study. Eur J Cancer. 2006, 42 (17): 2946-2953. 10.1016/j.ejca.2006.06.020.CrossRefPubMed
18.
go back to reference Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, Yamamori S, Sakamoto G: Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001, 92 (12): 2965-2974. 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO;2-A.CrossRefPubMed Tsuda H, Akiyama F, Terasaki H, Hasegawa T, Kurosumi M, Shimadzu M, Yamamori S, Sakamoto G: Detection of HER-2/neu (c-erb B-2) DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression. Cancer. 2001, 92 (12): 2965-2974. 10.1002/1097-0142(20011215)92:12<2965::AID-CNCR10156>3.0.CO;2-A.CrossRefPubMed
19.
go back to reference Rodriguez Moguel L, Vega Ramos B: [Reproducibility of Her-2/neu overexpression with HERCEP test in invasive ductal breast cancer]. Ginecol Obstet Mex. 2002, 70: 601-606.PubMed Rodriguez Moguel L, Vega Ramos B: [Reproducibility of Her-2/neu overexpression with HERCEP test in invasive ductal breast cancer]. Ginecol Obstet Mex. 2002, 70: 601-606.PubMed
20.
go back to reference Dolan M, Snover D: Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol. 2005, 123 (5): 766-770. 10.1309/Q0DGL26RUCK1K5EV.CrossRefPubMed Dolan M, Snover D: Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice. Am J Clin Pathol. 2005, 123 (5): 766-770. 10.1309/Q0DGL26RUCK1K5EV.CrossRefPubMed
21.
go back to reference Diaz NM: Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control. 2001, 8 (5): 415-418.PubMed Diaz NM: Laboratory testing for HER2/neu in breast carcinoma: an evolving strategy to predict response to targeted therapy. Cancer Control. 2001, 8 (5): 415-418.PubMed
22.
go back to reference Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999, 17 (7): 1983-1987.PubMed Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ: Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol. 1999, 17 (7): 1983-1987.PubMed
23.
go back to reference Leong AS, Formby M, Haffajee Z, Clarke M, Morey A: Refinement of immunohistologic parameters for Her2/neu scoring validation by FISH and CISH. Appl Immunohistochem Mol Morphol. 2006, 14 (4): 384-389. 10.1097/01.pai.0000210415.53493.d4.CrossRefPubMed Leong AS, Formby M, Haffajee Z, Clarke M, Morey A: Refinement of immunohistologic parameters for Her2/neu scoring validation by FISH and CISH. Appl Immunohistochem Mol Morphol. 2006, 14 (4): 384-389. 10.1097/01.pai.0000210415.53493.d4.CrossRefPubMed
24.
go back to reference Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001, 19 (10): 2714-2721.PubMed Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM: Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol. 2001, 19 (10): 2714-2721.PubMed
25.
go back to reference Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25 (1): 118-145. 10.1200/JCO.2006.09.2775.CrossRefPubMed Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007, 25 (1): 118-145. 10.1200/JCO.2006.09.2775.CrossRefPubMed
26.
go back to reference Rinner O, Gegenfurtner KR: Time course of chromatic adaptation for color appearance and discrimination. Vision Res. 2000, 40 (14): 1813-1826. 10.1016/S0042-6989(00)00050-X.CrossRefPubMed Rinner O, Gegenfurtner KR: Time course of chromatic adaptation for color appearance and discrimination. Vision Res. 2000, 40 (14): 1813-1826. 10.1016/S0042-6989(00)00050-X.CrossRefPubMed
27.
go back to reference Byrne A, Hilbert DR: Color realism and color science. Behav Brain Sci. 2003, 26 (1): 3-21.PubMed Byrne A, Hilbert DR: Color realism and color science. Behav Brain Sci. 2003, 26 (1): 3-21.PubMed
28.
go back to reference Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, et al: Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 2008, 110 (3): 417-26. 10.1007/s10549-007-9736-z.CrossRefPubMed Turbin DA, Leung S, Cheang MC, Kennecke HA, Montgomery KD, McKinney S, Treaba DO, Boyd N, Goldstein LC, Badve S, et al: Automated quantitative analysis of estrogen receptor expression in breast carcinoma does not differ from expert pathologist scoring: a tissue microarray study of 3,484 cases. Breast Cancer Res Treat. 2008, 110 (3): 417-26. 10.1007/s10549-007-9736-z.CrossRefPubMed
29.
go back to reference Ciampa A, Xu B, Ayata G, Baiyee D, Wallace J, Wertheimer M, Edmiston K, Khan A: HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. Appl Immunohistochem Mol Morphol. 2006, 14 (2): 132-137. 10.1097/01.pai.0000150516.75567.13.CrossRefPubMed Ciampa A, Xu B, Ayata G, Baiyee D, Wallace J, Wertheimer M, Edmiston K, Khan A: HER-2 status in breast cancer: correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system. Appl Immunohistochem Mol Morphol. 2006, 14 (2): 132-137. 10.1097/01.pai.0000150516.75567.13.CrossRefPubMed
30.
go back to reference Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, et al: Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology. 2006, 48 (3): 258-267. 10.1111/j.1365-2559.2005.02322.x.CrossRefPubMed Tawfik OW, Kimler BF, Davis M, Donahue JK, Persons DL, Fan F, Hagemeister S, Thomas P, Connor C, Jewell W, et al: Comparison of immunohistochemistry by automated cellular imaging system (ACIS) versus fluorescence in-situ hybridization in the evaluation of HER-2/neu expression in primary breast carcinoma. Histopathology. 2006, 48 (3): 258-267. 10.1111/j.1365-2559.2005.02322.x.CrossRefPubMed
31.
go back to reference Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL: HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005, 58 (7): 710-714. 10.1136/jcp.2004.023424.CrossRefPubMedPubMedCentral Ellis CM, Dyson MJ, Stephenson TJ, Maltby EL: HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol. 2005, 58 (7): 710-714. 10.1136/jcp.2004.023424.CrossRefPubMedPubMedCentral
32.
go back to reference Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Osamura RY, Tani Y: Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis. Pathol Int. 2001, 51 (1): 33-36. 10.1046/j.1440-1827.2001.01162.x.CrossRefPubMed Hatanaka Y, Hashizume K, Kamihara Y, Itoh H, Tsuda H, Osamura RY, Tani Y: Quantitative immunohistochemical evaluation of HER2/neu expression with HercepTestTM in breast carcinoma by image analysis. Pathol Int. 2001, 51 (1): 33-36. 10.1046/j.1440-1827.2001.01162.x.CrossRefPubMed
33.
go back to reference Joshi AS, Sharangpani GM, Porter K, Keyhani S, Morrison C, Basu AS, Gholap GA, Gholap AS, Barsky SH: Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A. 2007, 71 (5): 273-285.CrossRefPubMed Joshi AS, Sharangpani GM, Porter K, Keyhani S, Morrison C, Basu AS, Gholap GA, Gholap AS, Barsky SH: Semi-automated imaging system to quantitate Her-2/neu membrane receptor immunoreactivity in human breast cancer. Cytometry A. 2007, 71 (5): 273-285.CrossRefPubMed
34.
go back to reference Skaland I, Ovestad I, Janssen EA, Klos J, Kjellevold KH, Helliesen T, Baak JP: Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer. J Clin Pathol. 2008, 61 (1): 68-71. 10.1136/jcp.2007.046763.CrossRefPubMed Skaland I, Ovestad I, Janssen EA, Klos J, Kjellevold KH, Helliesen T, Baak JP: Comparing subjective and digital image analysis HER2/neu expression scores with conventional and modified FISH scores in breast cancer. J Clin Pathol. 2008, 61 (1): 68-71. 10.1136/jcp.2007.046763.CrossRefPubMed
35.
go back to reference Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4 (7): 844-847. 10.1038/nm0798-844.CrossRefPubMed Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998, 4 (7): 844-847. 10.1038/nm0798-844.CrossRefPubMed
36.
go back to reference Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D: Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003, 34 (10): 1001-1008. 10.1053/S0046-8177(03)00411-8.CrossRefPubMed Makretsov N, Gilks CB, Coldman AJ, Hayes M, Huntsman D: Tissue microarray analysis of neuroendocrine differentiation and its prognostic significance in breast cancer. Hum Pathol. 2003, 34 (10): 1001-1008. 10.1053/S0046-8177(03)00411-8.CrossRefPubMed
37.
go back to reference Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K, Gilks CB, Rijn van de M: Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 2002, 161 (5): 1557-1565.CrossRefPubMedPubMedCentral Liu CL, Prapong W, Natkunam Y, Alizadeh A, Montgomery K, Gilks CB, Rijn van de M: Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 2002, 161 (5): 1557-1565.CrossRefPubMedPubMedCentral
38.
go back to reference Liu CL, Montgomery KD, Natkunam Y, West RB, Nielsen TO, Cheang MC, Turbin DA, Marinelli RJ, Rijn van de M, Higgins JP: TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol. 2005, 18 (12): 1641-1648.PubMed Liu CL, Montgomery KD, Natkunam Y, West RB, Nielsen TO, Cheang MC, Turbin DA, Marinelli RJ, Rijn van de M, Higgins JP: TMA-Combiner, a simple software tool to permit analysis of replicate cores on tissue microarrays. Mod Pathol. 2005, 18 (12): 1641-1648.PubMed
41.
go back to reference Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, Hastie T, McKinney S, Nielsen TO, Huntsman DG, et al: New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat. 2008, 112 (3): 453-9. 10.1007/s10549-007-9887-y.CrossRefPubMed Jensen KC, Turbin DA, Leung S, Miller MA, Johnson K, Norris B, Hastie T, McKinney S, Nielsen TO, Huntsman DG, et al: New cutpoints to identify increased HER2 copy number: analysis of a large, population-based cohort with long-term follow-up. Breast Cancer Res Treat. 2008, 112 (3): 453-9. 10.1007/s10549-007-9887-y.CrossRefPubMed
42.
go back to reference Efron BTR: An Introduction to the Bootstrap. 1993, Boca Raton: CHAPMAN & HALL/CRCCrossRef Efron BTR: An Introduction to the Bootstrap. 1993, Boca Raton: CHAPMAN & HALL/CRCCrossRef
43.
go back to reference Lehr HA, Jacobs TW, Yaziji H, Schnitt SJ, Gown AM: Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol. 2001, 115 (6): 814-822. 10.1309/AJ84-50AK-1X1B-1Q4C.CrossRefPubMed Lehr HA, Jacobs TW, Yaziji H, Schnitt SJ, Gown AM: Quantitative evaluation of HER-2/neu status in breast cancer by fluorescence in situ hybridization and by immunohistochemistry with image analysis. Am J Clin Pathol. 2001, 115 (6): 814-822. 10.1309/AJ84-50AK-1X1B-1Q4C.CrossRefPubMed
44.
go back to reference Thor A: HER2–a discussion of testing approaches in the USA. Ann Oncol. 2001, 12 (Suppl 1): S101-107. 10.1023/A:1011120309910.CrossRefPubMed Thor A: HER2–a discussion of testing approaches in the USA. Ann Oncol. 2001, 12 (Suppl 1): S101-107. 10.1023/A:1011120309910.CrossRefPubMed
45.
go back to reference Gown AM: Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008, 21 (Suppl 2): S8-S15. 10.1038/modpathol.2008.34.CrossRefPubMed Gown AM: Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol. 2008, 21 (Suppl 2): S8-S15. 10.1038/modpathol.2008.34.CrossRefPubMed
46.
go back to reference Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL: Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol. 2007, 25 (34): 5418-5425. 10.1200/JCO.2007.12.8033.CrossRefPubMed Moeder CB, Giltnane JM, Harigopal M, Molinaro A, Robinson A, Gelmon K, Huntsman D, Camp RL, Rimm DL: Quantitative justification of the change from 10% to 30% for human epidermal growth factor receptor 2 scoring in the American Society of Clinical Oncology/College of American Pathologists guidelines: tumor heterogeneity in breast cancer and its implications for tissue microarray based assessment of outcome. J Clin Oncol. 2007, 25 (34): 5418-5425. 10.1200/JCO.2007.12.8033.CrossRefPubMed
47.
go back to reference Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A: The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol. 2004, 122 (1): 51-60. 10.1309/E9B55JYHD84L8Y17.CrossRefPubMed Rhodes A, Borthwick D, Sykes R, Al-Sam S, Paradiso A: The use of cell line standards to reduce HER-2/neu assay variation in multiple European cancer centers and the potential of automated image analysis to provide for more accurate cut points for predicting clinical response to trastuzumab. Am J Clin Pathol. 2004, 122 (1): 51-60. 10.1309/E9B55JYHD84L8Y17.CrossRefPubMed
48.
go back to reference Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL: HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001, 14 (11): 1079-1086. 10.1038/modpathol.3880440.CrossRefPubMed Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL: HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol. 2001, 14 (11): 1079-1086. 10.1038/modpathol.3880440.CrossRefPubMed
49.
go back to reference Santinelli A, Baccarini M, Colanzi P, Stramazzotti D, Fabris G: Immunohistochemical evaluation of HER-2/neu expression in infiltrating breast carcinoma: a study of reproducibility. Anal Quant Cytol Histol. 2002, 24 (1): 54-62.PubMed Santinelli A, Baccarini M, Colanzi P, Stramazzotti D, Fabris G: Immunohistochemical evaluation of HER-2/neu expression in infiltrating breast carcinoma: a study of reproducibility. Anal Quant Cytol Histol. 2002, 24 (1): 54-62.PubMed
50.
go back to reference Bloom K, Harrington D: Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol. 2004, 121 (5): 620-630. 10.1309/Y73U8X72B68TMGH5.CrossRefPubMed Bloom K, Harrington D: Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy. Am J Clin Pathol. 2004, 121 (5): 620-630. 10.1309/Y73U8X72B68TMGH5.CrossRefPubMed
51.
go back to reference Hashizume K, Hatanaka Y, Kamihara Y, Kato T, Hata S, Akashi S, Kato T, Koyatsu J, Tani Y, Tsujimoto M, et al: Interlaboratory comparison in HercepTest assessment of HER2 protein status in invasive breast carcinoma fixed with various formalin-based fixatives. Appl Immunohistochem Mol Morphol. 2003, 11 (4): 339-344.CrossRefPubMed Hashizume K, Hatanaka Y, Kamihara Y, Kato T, Hata S, Akashi S, Kato T, Koyatsu J, Tani Y, Tsujimoto M, et al: Interlaboratory comparison in HercepTest assessment of HER2 protein status in invasive breast carcinoma fixed with various formalin-based fixatives. Appl Immunohistochem Mol Morphol. 2003, 11 (4): 339-344.CrossRefPubMed
52.
go back to reference Gouvea AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H: Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol. 2006, 14 (1): 103-108. 10.1097/01.pai.0000155794.64525.11.CrossRefPubMed Gouvea AP, Milanezi F, Olson SJ, Leitao D, Schmitt FC, Gobbi H: Selecting antibodies to detect HER2 overexpression by immunohistochemistry in invasive mammary carcinomas. Appl Immunohistochem Mol Morphol. 2006, 14 (1): 103-108. 10.1097/01.pai.0000155794.64525.11.CrossRefPubMed
53.
go back to reference Ainsworth R, Bartlett JM, Going JJ, Mallon EA, Forsyth A, Richmond J, Angerson W, Watters A, Dunne B: IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma. J Clin Pathol. 2005, 58 (10): 1086-1090. 10.1136/jcp.2004.021576.CrossRefPubMedPubMedCentral Ainsworth R, Bartlett JM, Going JJ, Mallon EA, Forsyth A, Richmond J, Angerson W, Watters A, Dunne B: IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest in breast carcinoma. J Clin Pathol. 2005, 58 (10): 1086-1090. 10.1136/jcp.2004.021576.CrossRefPubMedPubMedCentral
54.
go back to reference Lopez-Guerrero JA, Navarro S, Noguera R, Almenar S, Pellin A, Vazquez C, Llombart-Bosch A: Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures. Arkh Patol. 2003, 65 (1): 50-55.PubMed Lopez-Guerrero JA, Navarro S, Noguera R, Almenar S, Pellin A, Vazquez C, Llombart-Bosch A: Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures. Arkh Patol. 2003, 65 (1): 50-55.PubMed
55.
go back to reference Tsuda H, Tani Y, Hasegawa T, Fukutomi T: Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma. Pathol Int. 2001, 51 (1): 26-32. 10.1046/j.1440-1827.2001.01163.x.CrossRefPubMed Tsuda H, Tani Y, Hasegawa T, Fukutomi T: Concordance in judgments among c-erbB-2 (HER2/neu) overexpression detected by two immunohistochemical tests and gene amplification detected by Southern blot hybridization in breast carcinoma. Pathol Int. 2001, 51 (1): 26-32. 10.1046/j.1440-1827.2001.01163.x.CrossRefPubMed
56.
go back to reference Tsuda H, Sasano H, Akiyama F, Kurosumi M, Hasegawa T, Osamura RY, Sakamoto G: Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol Int. 2002, 52 (2): 126-134. 10.1046/j.1440-1827.2002.01327.x.CrossRefPubMed Tsuda H, Sasano H, Akiyama F, Kurosumi M, Hasegawa T, Osamura RY, Sakamoto G: Evaluation of interobserver agreement in scoring immunohistochemical results of HER-2/neu (c-erbB-2) expression detected by HercepTest, Nichirei polyclonal antibody, CB11 and TAB250 in breast carcinoma. Pathol Int. 2002, 52 (2): 126-134. 10.1046/j.1440-1827.2002.01327.x.CrossRefPubMed
57.
go back to reference Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G: Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology. 2003, 43 (4): 354-362. 10.1046/j.1365-2559.2003.01708.x.CrossRefPubMed Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G: Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology. 2003, 43 (4): 354-362. 10.1046/j.1365-2559.2003.01708.x.CrossRefPubMed
58.
go back to reference Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C, et al: Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology. 2003, 42 (4): 337-347. 10.1046/j.1365-2559.2003.01598.x.CrossRefPubMed Vincent-Salomon A, MacGrogan G, Couturier J, Arnould L, Denoux Y, Fiche M, Jacquemier J, Mathieu MC, Penault-Llorca F, Rigaud C, et al: Calibration of immunohistochemistry for assessment of HER2 in breast cancer: results of the French multicentre GEFPICS study. Histopathology. 2003, 42 (4): 337-347. 10.1046/j.1365-2559.2003.01598.x.CrossRefPubMed
59.
go back to reference Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002, 94 (11): 855-857.CrossRefPubMed Roche PC, Suman VJ, Jenkins RB, Davidson NE, Martino S, Kaufman PA, Addo FK, Murphy B, Ingle JN, Perez EA: Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst. 2002, 94 (11): 855-857.CrossRefPubMed
60.
go back to reference Ellsworth RE, Ellsworth DL, Patney HL, Deyarmin B, Love B, Hooke JA, Shriver CD: Amplification of HER2 is a marker for global genomic instability. BMC Cancer. 2008, 8: 297-10.1186/1471-2407-8-297.CrossRefPubMedPubMedCentral Ellsworth RE, Ellsworth DL, Patney HL, Deyarmin B, Love B, Hooke JA, Shriver CD: Amplification of HER2 is a marker for global genomic instability. BMC Cancer. 2008, 8: 297-10.1186/1471-2407-8-297.CrossRefPubMedPubMedCentral
61.
go back to reference Bishop JW, Marcelpoil R, Schmid J: Machine scoring of Her2/neu immunohistochemical stains. Anal Quant Cytol Histol. 2002, 24 (5): 257-262.PubMed Bishop JW, Marcelpoil R, Schmid J: Machine scoring of Her2/neu immunohistochemical stains. Anal Quant Cytol Histol. 2002, 24 (5): 257-262.PubMed
62.
go back to reference Wen C-H, Lee J-J: Design and production of color calibration targets for digital input devices. Proceedings of the Photonics Taiwan 2000: 26 July 2000; Taipei, Taiwan. 2000, 148- Wen C-H, Lee J-J: Design and production of color calibration targets for digital input devices. Proceedings of the Photonics Taiwan 2000: 26 July 2000; Taipei, Taiwan. 2000, 148-
63.
go back to reference Walker RA: Quantification of immunohistochemistry–issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006, 49 (4): 406-410. 10.1111/j.1365-2559.2006.02514.x.CrossRefPubMed Walker RA: Quantification of immunohistochemistry–issues concerning methods, utility and semiquantitative assessment I. Histopathology. 2006, 49 (4): 406-410. 10.1111/j.1365-2559.2006.02514.x.CrossRefPubMed
64.
go back to reference Taylor CR, Levenson RM: Quantification of immunohistochemistry–issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006, 49 (4): 411-424. 10.1111/j.1365-2559.2006.02513.x.CrossRefPubMed Taylor CR, Levenson RM: Quantification of immunohistochemistry–issues concerning methods, utility and semiquantitative assessment II. Histopathology. 2006, 49 (4): 411-424. 10.1111/j.1365-2559.2006.02513.x.CrossRefPubMed
Metadata
Title
Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situhybridization (FISH): pathologist assessment compared to quantitative image analysis
Authors
Gulisa Turashvili
Samuel Leung
Dmitry Turbin
Kelli Montgomery
Blake Gilks
Rob West
Melinda Carrier
David Huntsman
Samuel Aparicio
Publication date
01-12-2009
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2009
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-9-165

Other articles of this Issue 1/2009

BMC Cancer 1/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine